Supply of Aseptically Prepared Dose Banded Medicines

Description

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion. Lot 1.1: BORTEZOMIB The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion. Lot 1.2: CARBOPLATIN The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion. Lot 1.3: CETUXIMAB The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion. Lot 1.4: CISPLATIN The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion. Lot 1.5: CYCLOPHOSPHAMIDE The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion. Lot 1.6: CYTARABINE The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion. Lot 1.7: DESFERRIOXAMINE The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion. Lot 1.8: DOCETAXEL The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion. Lot 1.9: DOXORUBICIN The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion. Lot 1.10: EPIRUBICIN The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion. Lot 1.11: FLUOROURACIL The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion. Lot 1.12: GANCICLOVIR The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion. Lot 1.13: GEMCITABINE The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion. Lot 1.14: INFLIXIMAB The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion. Lot 1.15: IRINOTECAN The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion. Lot 1.16: METHOTREXATE The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion. Lot 1.17: NIVOLUMAB The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion. Lot 1.18: OXALIPLATIN The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Lot 1.19: PACLITAXEL The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion. Lot 1.20: PEMBROLIZUMAB The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion. Lot 1.21: PERTUZUMAB The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion. Lot 1.22: RITUXIMAB The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion. Lot 1.23: TRASTUZUMAB SC The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion. Lot 1.24: TRASTUZUMAB IV The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion. Lot 1.25: VINCRISTINE The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion. Lot 2: Aseptically Prepared Dose Banded Medicines The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion. Lot 3: CIVAS (Centralised Intravenous Additive Service) The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion. Lot 4: Patient Specific Chemotherapy The Tender is to establish a framework agreement for the supply of a range of aseptically prepared patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists. The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion.